

# Pharma Innovation Report — Paracetamol

Generated: 2025-12-09 10:05:18

## Executive summary

This report summarizes automated research for **paracetamol**. Sources: PubMed literature, ClinicalTrials.gov (if available), Patent landscape (mock), Market & trade mock data, internal document summaries and web intelligence.

## Unmet medical needs (AI-extracted)

- Need for improved safety profile
- Lack of long-acting formulations
- Limited studies in pediatric population
- Potential off-label benefit in new therapeutic areas

## PubMed — sample articles

PMID	Title (short)	Journal	PubDate
37436926	Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention, drug metabolism and molecular biology.	Expert Opin Drug Metab Toxicol	2006 Dec 1
34681816	Paracetamol (Acetaminophen) and the Developing Brain.	Int J Mol Sci	2021 Oct 15
33125495	Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever in Pain Network Open Young Children: A Systematic Review.	JAMA Netw Open	2020 Oct 21
36414224	Pharmaceutical treatment of osteoarthritis.	Osteoarthritis Cartilage	2023 Apr
29863746	Long-term adverse effects of paracetamol - a review.	Br J Clin Pharmacol	2018 Oct
35440176	Paracetamol for multimodal analgesia.	Pain Manag	2022 Sep
29473717	Interventions for paracetamol (acetaminophen) overdose.	Cochrane Database Syst Rev	2018 Feb 23
29341895	Prenatal paracetamol exposure and child neurodevelopment: A review.	Horm Behav	2018 May

## Clinical trials (summary)

NCTId	Condition	Title	Phase	Status

## Patent landscape (mock)

- US-754433: paracetamol novel formulation — Active (expiry: 2032)
- US-307309: paracetamol novel formulation — Expired (expiry: 2036)
- US-941005: paracetamol novel formulation — Pending (expiry: 2039)

- US-252533: paracetamol novel formulation — Expired (expiry: 2026)
- US-294185: paracetamol novel formulation — Active (expiry: 2037)

## Market insights (IQVIA mock)

Market size (2024): • CAGR: **10%**

## EXIM trade highlights

## Web intelligence (sample citations)

- World Health Organization guidance on paracetamol — who.int — <https://who.int/guidance/paracetamol>
- Recent review: off-label uses of paracetamol — journal-review.org — <https://journal-review.org/paracetamol-review>
- Patient forum discussion on paracetamol side effects — healthforums.example — <https://healthforums.example/paracetamol>
- Regulatory safety update on paracetamol — regulator.example — <https://regulator.example/alerts/paracetamol>

## Internal insights

- Field team reported increased usage trends in chronic patients.
- Opportunity: Improved formulation may provide advantage in Tier-2 markets.
- Competitor analysis indicates pricing pressure but strong prescription loyalty.
- Pharmacovigilance notes minimal adverse trends year-over-year.

## Methodology & Notes

This report was generated automatically by the Agentic AI pipeline. ClinicalTrials.gov data may be limited due to API rate limits; patent data is mock unless linked to a USPTO/Global API. Market and trade outputs are synthetic mock data for demonstration purposes.